Molbio Diagnostics — Pre-IPO Research Report

What the company is (and how it makes money)

• Molbio Diagnostics develops, manufactures, and commercializes a range of diagnostic solutions, primarily focusing on molecular diagnostics.
• Its flagship product is the Truenat platform, a portable, real-time PCR (Polymerase Chain Reaction) device designed for rapid, point-of-care testing.
• The company offers diagnostic tests for various infectious diseases, including Tuberculosis (TB), COVID-19, HIV, Hepatitis, and others, using proprietary Truenat chips and reagents.
• Revenue is generated from the sale of the Truenat devices themselves and the recurring sale of disease-specific Truenat chips/reagents required for each test.
• The platform aims to decentralize molecular diagnostics, making advanced testing accessible in remote and resource-limited settings.

Financial snapshot (officially disclosed only)

• As per the DRHP filed with SEBI, Molbio Diagnostics reported total revenue from operations of INR 1,317.34 crore for Fiscal 2022, up from INR 332.99 crore in Fiscal 2021.
• The company recorded a profit after tax of INR 200.73 crore for Fiscal 2022, compared to INR 117.84 crore in Fiscal 2021, per the DRHP.
• The significant growth in revenue and profitability during Fiscal 2021 and 2022 was substantially driven by increased demand for COVID-19 testing using its Truenat platform, as disclosed in the DRHP.
• More recent financial figures beyond Fiscal 2022 are not officially disclosed and would be available in the updated Red Herring Prospectus (RHP) or subsequent filings.

The moat

• **Proprietary Technology & IP**: The Truenat platform, with its patented chip-based PCR technology, offers a unique value proposition for rapid, point-of-care molecular diagnostics, creating a barrier to entry for direct competitors.
• **Regulatory Approvals & Endorsements**: The platform has received critical approvals from Indian regulatory bodies like ICMR and a notable endorsement from the World Health Organization (WHO) for TB diagnostics, enhancing credibility and market acceptance.
• **Decentralized Testing Capability**: The portability and ease of use of the Truenat system enable molecular testing in remote and primary healthcare settings, expanding access beyond traditional labs and creating a distinct market niche.
• **Recurring Revenue Model**: Beyond the initial sale of devices, the continuous need for proprietary Truenat chips and reagents for each test creates a predictable, high-margin recurring revenue stream.
• **Established Network & Brand**: Molbio Diagnostics has built a significant distribution network, particularly strengthened during the pandemic, and the Truenat brand has become recognized in the Indian diagnostics landscape.

Where it is in the IPO pipeline

• Molbio Diagnostics filed its Draft Red Herring Prospectus (DRHP) with SEBI in September 2022.
• The company received SEBI's observation letter, effectively an approval to proceed with the IPO, in December 2022.
• The DRHP outlined a proposed IPO structure comprising a fresh issue of equity shares aggregating up to INR 1,500 crore and an Offer for Sale (OFS) of up to 4.23 crore equity shares by existing shareholders.
• Despite SEBI approval, the company has not yet launched its IPO, indicating a potential strategic delay or re-evaluation of market conditions.
• Before launching the IPO, Molbio Diagnostics would need to file a Red Herring Prospectus (RHP) with updated financials and other details.

How to evaluate it (a diligence checklist)

• **Review the Red Herring Prospectus (RHP)**: Thoroughly examine the RHP once filed, paying close attention to the updated financials, detailed risk factors, business strategy, and use of IPO proceeds.
• **Analyze Revenue Mix and Growth Drivers**: Disaggregate revenue by product (device vs. reagents), disease area (COVID vs. non-COVID), and customer segment (government vs. private) to understand underlying growth trends and dependencies.
• **Assess Unit Economics**: Evaluate the average selling price of Truenat devices, the recurring revenue per device from reagent sales, and the profitability margins for different tests.
• **Evaluate Competitive Landscape**: Research Molbio's direct and indirect competitors in the point-of-care molecular diagnostics space, comparing technology, pricing, market penetration, and R&D pipelines.
• **Scrutinize Regulatory Approvals and Pipeline**: Verify the status and validity of all key regulatory approvals for existing products and assess the robustness and timelines of the R&D pipeline for new tests.
• **Examine Related Party Transactions and Corporate Governance**: Review the DRHP for any related-party transactions and assess the corporate governance practices, board composition, and promoter shareholding structure.

Official references

• The company's Draft Red Herring Prospectus (DRHP) filed with SEBI in September 2022
• The SEBI observation letter for Molbio Diagnostics dated December 2022
• The company's official website for product and corporate information
• Audited financial statements filed with the Ministry of Corporate Affairs (MCA)

Frequently asked questions